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ABSTRACT
Background A child with autism and mild microcephaly
was found to have a de novo 3.3 Mb microdeletion on
chromosome 1p34.2p34.3. The hypothesis is tested that
this microdeletion contains one or more genes that
underlie the autism phenotype in this child and in other
children with autism spectrum disorders.
Methods To search for submicroscopic chromosomal
rearrangements in the child, array comparative genomic
hybridisation (aCGH) was performed using a 19 K whole
genome human bacterial artiﬁcial chromosome (BAC)
array and the Illumina 610-Quad BeadChip microarray.
Ingenuity pathway analysis (IPA) was used to construct
functional biological networks to identify candidate
autism genes. To identify putative functional variants in
candidate genes, mutation screening was performed
using polymerase chain reaction (PCR) based Sanger
sequencing in 512 unrelated autism patients and 462
control subjects.
Results A de novo 3.3 Mb deletion containing
w43 genes in chromosome 1p34.2p34.3 was identiﬁed
and subsequently conﬁrmed using ﬂuorescence in situ
hybridization (FISH). Literature review and bioinformatics
analyses identiﬁed Regulating Synaptic Membrane
Exocytosis 3 (RIMS3) as the most promising autism
candidate gene. Mutation screening of this gene in
autism patients identiﬁed ﬁve inherited coding variants,
including one (p.E177A) that segregated with the autism
phenotype in a sibship, was predicted to be deleterious,
and was absent in 1161 controls.
Conclusions This case report and mutation screening
data suggest that RIMS3 is an autism causative or
contributory gene. Functional studies of RIMS3 variants
such as p.E177A should provide additional insight into the
role of synaptic proteins in the pathophysiology of autism.
INTRODUCTION
Autism is characterised by deﬁcits in reciprocal
social interaction, disrupted verbal and non-verbal
communication, and restricted interests and repet-
itive behaviours, and is known to have a strong
genetic component.
1 2 Cytogenetic studies indicate
that w3e4% of autism patients have chromosomal
imbalances
3e5 that include maternal 15q11q13
duplications (w1e2% of patients) and deletions of
2q37, 22q11.2 and 22q13.3.
46Higher resolution
approaches using array comparative genomic
hybridisation (aCGH) and single nucleotide poly-
morphism microarrays have recently identiﬁed
submicroscopic copy number variants (CNVs),
7e10
including recurrent microdeletions and duplications
of 16p11.2 that have been reported in w1% of
autism patients.
81 11 2Importantly, the discovery
of chromosomal abnormalities and CNVs has led
to the identiﬁcation of rare intragenic mutat-
ions through deep resequencing of autism candi-
date genes, including NLGN3 and NLGN4,
13
NRXN1,
10 14 15 SHANK3
16e18 and CNTNAP2.
19e21
Although mutations in these genes account for only
a small proportion of individuals with autism, they
nonetheless provide insight into potential biological
mechanisms that may underlie autism, such as
synaptic dysfunction and abnormal brain connec-
tivity.
22 23
Here, we report the case of a boy with autism,
microcephaly, and other dysmorphic features in
whom aCGH detected a w3.3-Mb interstitial dele-
tion in chromosome 1p34.2p34.3 that contains w43
genes, including Regulating synaptic membrane
exocytosis protein 3 (RIMS3), a gene previously
shown to be dysregulated in autism subjects.
24 We
examined the role of RIMS3 in 512 unrelated autism
subjects by performing mutation analyses to look
for putative functional variants.
CLINICAL REPORT
The boy (LP99-105) was born at term to healthy
and unrelated parents, and appeared normal except
for right hydronephrosis and vesicoureteral reﬂux,
which both resolved. His head circumference was
normal at birth, but decelerated after 7 months and
subsequently followed a curve at or just below
e2S D( ﬁgure 1A). His early motor development
was normal, but he walked late at 16 months. He
used his ﬁrst few words at 15 months and slowly
increased to 50e75 words by 2.5 years, but then
progressively stopped using almost all speech by
3 years.
Onexamination,hehadanormalfacialappearance
at 1 year (ﬁgure 1B), but by 10 years he had a long
narrow face and deep set or sunken eyes (ﬁgure 1C).
His general and neurological examinations were
normal, including good motor coordination. Serial
exams between 2 and10 years alldemonstrated poor
social communication including poor eye contact
and limited interactive play, striking anxiety, difﬁ-
culty with transitions, constant chewing, short
attention span, poor sleep pattern, and repetitive
activities such as bouncing on an exercise ball. Brain
magnetic resonance imaging (MRI) at 1 year
demonstrated mildly prominent extra-axial spaces,
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Original articlebut was otherwise normal. Serial audiograms done during his ﬁrst
several years of life demonstrated normal hearing.
He was diagnosed with autistic disorder at age 4 years
at a university based assessment clinic for children with
developmental disorders. On the Autism Diagnostic Observation
ScheduleeGeneric (ADOS-G),
25 he exceeded the autism cut-off
score on the communication, social, and communication plus
social domains, thus meeting the criterion for an Autism
Figure 1 (A) The patient’s head circumference (HC) was normal at birth, but decelerated after 7 months and subsequently followed a curve at e3 SD.
Y axis shows HC size in both centimetres and inches. X axis indicates age. The top and bottom dashed curves represent HC at +2 SD (98%) and e2S D
(2%), respectively, in relation to the mean (50%) HC curve (solid). Serial HC measurements for the patient are represented as red dots. (B) The patient’s
facial appearance is normal at 1 year of age. (C) At 10 years the boy has subtle dysmorphism with a long narrow face and deep set or sunken eyes.
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Original articleDiagnostic Observation ScheduleeGeneric classiﬁcation of
autism (domain scores: communication 6; social 12; stereotyped
behaviours and restricted interests 4). The diagnosis was further
supported by meeting the cut-off scores of autism on the Autism
Diagnostic IntervieweRevised (ADI-R)
26 with his mother as the
informant. More widespread developmental abnormalities were
documented at 4 years based on anoverall standard score of 28 on
the Scales of Independent BehavioreRevised,
27 a parent report
measure of adaptive behaviour. This falls in the “limited to very
limited” range, equivalent to behaviours at 18 months in typi-
cally developing children.
During the subsequent 6 years, he has not regained any
language skills, except for using several signs inconsistently. He
developed a striking fear response when placed in a car at age
9 years that has persisted for more than 3 years. Chromosome
analysis and polymerase chain reaction (PCR) based fragile X
testing were normal, and no other genetic tests were done. This
boy is not part ofthe Autism Genetics Resource Exchange (AGRE,
LosAngeles,California,USA)consortium(http://www.agre.org/).
SUBJECTS AND METHODS
Autism and control subjects
We obtained phenotype data and DNA from the 1p34 deletion
proband under a protocol approved by the Institutional Review
Board at the University of Chicago. The remaining autism
probands selected for this study were a subset of the AGRE
subjects that were collected with informed consent and insti-
tutional review board approval.
28 The AGRE cohort consisted of
512 unrelated autism subjects (151 females and 355 males) from
84 simplex and 428 multiplex families. Subjects who missed
criteria for autism on the ADI-R were classiﬁed as having ‘Not
Quite Autism’ (NQA) if their scores on each ADI-R behavioural
domain were within one point of the criteria, or if they met
criteria for each domain except for age of onset <3 years of age.
Fragile X testing was performed in all families and a subset of
families had karyotyping and CNVanalyses performed. Genomic
DNA from control subjects (225 females and 237 males) was
obtained from the National Institute of Mental Health Human
Genetics Initiative control sample set. These subjects were
screened for Axis I mental health disorders and none were
reported as having autism. A summary of the ethnic origins of
the autism patients and control subjects is provided in supple-
mentary table 1.
Array comparative genomic hybridisation
We performed aCGH on the patient using a 19-K whole genome
tiling path bacterial artiﬁcial chromosome (BAC) microarray as
previously described.
7 We reﬁned the size of the 1p34.2p34.3
microdeletion using the Illumina 610-Quad BeadChip microarray
(Illumina Inc, San Diego, California, USA, http://www.illumina.com/).
Fluorescence in situ hybridisation (FISH) and microsatellite
analyses
FISH and microsatellite analyses were performed using standard
techniques (supplementary materials).
DNA ampliﬁcation and sequencing
PCR primers were designed using MIT Primer3 with M13
forward and reverse tails added to each primer to facilitate high
throughput DNA sequencing (supplementary table 2). DNA
ampliﬁcation and puriﬁcation were performed using standard
conditions and protocols (supplementary materials).
Pathway analyses
A RIMS3 network was predicted through the use of Ingenuity
Pathways Analysis software (Ingenuity Systems Inc, Redwood
City, California, USA; http://www.ingenuity.com/). To generate
this network, a dataset of known autism genes (ie, focus genes)
was uploaded into the application. The Ingenuity Pathways
Knowledge Base was used to identify interactions between the
focus genes and other gene objects. The network was then
algorithmically generated based on their connectivity. The
network was comprised of ‘nodes’dthat is, the gene or gene
product, connected by ‘edges’ that are biological relationships
supported by at least one publication. The network was then
trimmed to show a reﬁned network with minimal connections
between the autism focus genes.
Protein predictions
We used several applications to predict the effects of missense
substitutions on protein function including SIFT (Sorting
Intolerant From Tolerant, http://sift.jcvi.org/),
29 PolyPhen
(Polymorphism Phenotyping, http://coot.embl.de/PolyPhen/),
30
and SNAP (http://cubic.bioc.columbia.edu/services/snap/).
31
RESULTS
Discovery of a 1p34.2p34.3 microdeletion in a child with autism
and microcephaly
We performed aCGH using a 19-K whole genome tiling path
BAC microarray in patient LP99-105, and detected a w3.3 Mb
deletion in chromosome 1p34.2p34.3 that extended from RP11-
769L8 to RP11-483I17 and included w47 genes (ﬁgure 2A). The
microdeletion was not detected in 372 control subjects analysed
on the same BAC array platform.
7 FISH studies conﬁrmed the
deletion in the proband (ﬁgure 2B), and microsatellite analysis
demonstrated that the deletion was de novo (data not shown).
We used the Illumina 610-Quad BeadChip microarray to
reﬁne the breakpoints to approximately chr1:39,794,296 and
chr1:43,058,974 (UCSC Genome Browser, http://genome.ucsc.
edu; Build 36.1; accessed November 2008), reducing the size of
the microdeletion by w56 kb and identifying w43 genes within
the deleted region.
We reviewed the Database of Genomic Variants (http://
projects.tcag.ca/variation/, Build 36; accessed November 2008)
to determine whether any CNVs in the general population were
present in the 1p34.2p34.3 microdeletion region. No CNVs
encompassed the entire deleted region, but we did ﬁnd several
smaller blocks of CNVs (ﬁgure 2A). The largest of these blocks,
independently characterised by four groups (variations 3289,
4219, 5487 and 8322), was w435 kb in size and contained 11
genes (PPIE, PPT1, TRIT1, OXCT2, MYCL1, BMP8B, MFSD2, RLF,
CAP1, TMCO2, and ZMPSTE24). Both copy number gains and
losses of this region were reported in the general population.
Identiﬁcation and characterisation of RIMS3 as a candidate
gene for autism
We hypothesised that rare mutations in one or more genes in the
1p34.2p34.3 microdeletion regiondexcluding the 11 in the
w435 kb polymorphic blockdmay be responsible for autism
in other affected individuals as well. Interrogation of these
w32 genes using published literature and online expression
databases identiﬁed RIMS3 as the most promising candidate.
Network analysis using Ingenuity Pathways Analysis software
demonstrated that RIMS3 directly interacts with the protein
tyrosine phosphatase PPFIA3 that belongs to the liprin-a gene
family (supplementary ﬁgure 1). RIMS3 was also associated with
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Original articleFigure 2 (A) Array comparative genome hybridisation (aCGH) using a bacterial artiﬁcial chromosome (BAC) microarray demonstrates a deletion
in chromosome 1p34.2. The aCGH plot shows the log2 ratio of the patient versus reference DNA on the vertical axis. Each individual BAC is represented
as a single blue dot and the horizontal axis shows the position of each BAC along chromosome 1. The deletion of 1p34.2 is indicated by an arrow
pointing to a vertical line of dots. Interrogation of the UCSC genome browser for the microdeletion region in this region identiﬁes w47 RefSeq genes
(shown below aCGH plot). Known copy number variants (CNVs) (orange blocks) and Indels (green blocks) are reported in the Database of Genomic
Variants track. (B) Fluorescence in situ hybridisation (FISH) analysis conﬁrms the deletion 1p34.2 aCGH results. The distal breakpoint boundary is
indicated where RP11-67o15 (green arrows) shows two normal signals while RP11-120G12 (red arrow) shows a single signal in the interphase nucleus.
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Original articlemany other autism candidate genes through an indirect inter-
action with FMR1, mutations of which cause fragile X syndrome
(OMIM 300624).
To test the hypothesis that mutations in RIMS3 underlie the
autism phenotype, we sequenced all RIMS3 coding regions, their
associated splice sites, and the 59 and 39untranslated regions in 512
unrelated autism patients. We also sequenced these regions in 462
control subjects to capture the natural genetic diversity of RIMS3
in the generalpopulation. In the autismsamples, we identiﬁed ﬁve
novel coding variants (three non-synonymous and two synony-
mous) that were absent in control subjects and not reported
in public DNA databases (Ensembl, http://www.ensembl.org/
and dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/, both
accessed February 2009) (table 1). Demographic data for these ﬁve
subjects, including sex, race, and ethnicity, are provided in table 1.
We also identiﬁed a 59untranslated region variant as well as one
intronic variant located 30 bp upstream of the third exon. We
found ﬁve different sequence changes in the controls (table 1).
Sequencing of parental DNA indicated that all ﬁve coding
variants were inherited. We performed segregation analysis in
families by sequencing each variant in affected and/or unaf-
fected siblings. In two multiplex families (AU0247 and AU0125,
ﬁgure 3), the variant segregated with the autism phenotype in
siblings. In family AU0247, the maternally inherited p.E177A
variant ﬁrst identiﬁed in patient HI0515 was also present in
a sibling with NQA, but absent in 1161 control subjects. We
reviewed available phenotype data on the carrier mother, who
had depression and symptoms of bipolar disorder and anxiety.
She also had a repaired cleft palate and had received speech
language therapy (the father had received speech language
therapy as well). The heterozygous sib had a ventricular septal
defect that closed spontaneously by 1 year and diastasis recti.
CNVanalysis on this family provided on the AGRE website ruled
out known CNVs associated with autism, including micro-
deletion of 22q11.
The p.E177A substitution, which changes a glutamic acid
(acidic and polar) to an alanine (neutral and nonpolar) residue,
was predicted to be deleterious according to both the SIFT and
SNAP programs. We determined the extent of conservation of
the E177 residue by comparing it against the RIMS3 primary
protein structure of other species (http://genome.ucsc.edu/, hg
18, accessed February 2009). E177 was conserved among all
18 eutherian mammals with data available, but differs from the
presumed ancestral Q177 residue found in six species of ﬁsh.
In family AU0125, the p.M260V exon 6 variant identiﬁed in
patient HI0686 was not predicted to affect protein function by
any of the three in silico protein programs. The carrier father had
obsessiveecompulsive disorder, depression, anxiety, and atten-
tion deﬁcit hyperactivity disorder. The presence of psychiatric
disorders in parents of children with autism has been observed
previously in several studies,
32e34 consistent with the hypothesis
of multiple genes with small additive effects in autism. By
parental report, both children had compulsions and rituals, and
difﬁculties with changes in routines and their environment. A
summary of phenotype information for the affected siblings in
families AU0247 and AU0125 is provided in table 2, with detailed
phenotype data for all members of families AU0247 and AU0125
included in the supplementary materials. Phenotypic data for the
other three families with coding variants (AU0783, AU0679, and
AU0841) were not available.
We also sequenced RIMS3 in the boy with the 3.3 Mb deletion
to test the hypothesis that the microdeletion might unmask
a recessive allele on the non-deleted chromosome. We did not
identify any putative functional coding variants.
In control subjects, we identiﬁed four coding variants that
were distinct from those identiﬁed in autism patients; one of
these was predicted to affect protein function (table 1). Three of
the four variants were located in exon 2, a region that did not
contain any of the ﬁve variants reported in the autism subjects.
The fourth variant, p.I162V, was located in the same coding
region in exon 4 that harboured the p.E177A substitution.
Interestingly, the subject harbouring this variant presented with
symptoms of obsessiveecompulsive disorder. Phenotypic data on
the parents of the control subjects were not available.
DISCUSSION
We report a boy with postnatal microcephaly, minor dysmorphic
features, mental retardation and autism associated with
a 3.3 Mb deletion involving w43 genes in chromosome
1p34.2p34.3. The deletion is large and de novo, leading us to
hypothesise that it is responsible for his abnormal phenotype.
However, the speciﬁc genes responsible for different features of
the 1p34.2p34.3 deletion phenotype are unknown.
Only a few patients with interstitial deletions of 1p34.2p34.3
have been reported. The closest match is the recent report of
a Dutch boy with a 4.1 Mb deletion that completely overlaps
the deletion we report, with loss of an additional 14 genes
including the glucose transporter gene SLC2A1.
35 Overall, he has
a more severe phenotype than our patient with severe mental
retardation and hypotonia, ‘profound’ microcephaly and
epilepsy, as well as heterotopia and ponto-cerebellar atrophy on
brain imaging. The more severe phenotype is not surprising given
the severe phenotype associated with loss of SLC2A1 alone
(OMIM 606777). Three other patients have been reported with
deletions involving this general region. One boy with a much
larger w17 Mb visible deletion had severe developmental
delay, poor growth, and microcephaly.
36 Two sibs who inherited
a juxtaposed inversion (inv 1p22.3p34.1) and deletion
(1p34.1p34.3) of this region presented with behaviour disorders,
although their intelligence and appearance were normal.
37 A
detailed genotypeephenotype analysis involving 1p34.2p34.3 in
these patients is provided in the supplementary materials.
Based on the reported altered regulation of RIMS3 in
autism
24 (see below) and our pathway analysis, we hypothesise
that mutations in the synaptic protein RIMS3 is the primary
contributor to the autism phenotype in the 1p34.2p34.3 micro-
deletion patient. A large number of autism related genes are
involved in synapse function, neuronal cell adhesion, or both.
38
Several of these have been implicated in autism based on cytoge-
netic rearrangements, CNVs or rare mutations, including NLGN3
andNLGN4,
13NRXN1,
10 14 15SHANK3,
16e18andCNTNAP2.
19e21
RIMS3 belongs to the RIM protein family that function as
important components of the presynaptic machinery for synaptic
vesicle fusion and neurotransmitter release.
39 Expression analysis
of RIMS3 in the rat demonstrated that it is exclusively expressed
in the brain
40 and protein studies indicated that RIMS3 was
detected only in rostral brain regions but not in spinal cord,
hindbrain, or midbrain.
40 Overexpression of RIMS3 has been
demonstrated to greatly facilitate Ca
2+ triggered exocytosis,
supporting a role for RIMS3 as a regulator of exocytosis in the
synaptic membrane.
40 One recent study demonstrated that
expression of RIMS3 is dysregulated in lymphoblastoid cells from
autism patients with either maternal duplications of 15q11q13
or fragileXsyndrome.
24Othershavereported increasedexpression
of RIMS3 in schizophrenia,
41 42 a neuropsychiatric disorder
hypothesised to have shared genetic aetiology with autism.
43
Thus, several lines of evidence converge to support the hypothesis
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rare mutations may underlie autism. However, we cannot exclude
the possibility that other genes within or near the w 3.3 Mb
1p34.2p34.3 deletion may contribute to autism.
To address whether RIMS3 point mutations underlie autism,
we sequenced the complete RIMS3 coding region in 512 unre-
lated autism patients. In total, ﬁve coding variants were identi-
ﬁed in autism patients that were absent in w460 controls. None
of these variants were de novo and all were inherited with no bias
between maternal versus paternal transmission. We used several
in silico programs to assess the functional impact of these vari-
ants on protein function, and identiﬁed one variant (p.E177A)
that was predicted to be deleterious. This variant segregated with
the autism phenotype in two sibs, was not identiﬁed in 1161
controls, and is highly conserved among eutherian mammals.
The p.E177A substitution resides in a C2B domain that is
known to bind to several proteins including a-liprins, SNAP-25,
and voltage gated calcium channels.
44 45 However, the critical
residues for some of these interactions are downstream of p.E177
and this amino acid is not conserved among the RIM family of
proteins.
40 a-Liprins are known to interact directly with CASK,
a calcium/calmodulin dependent serine protein kinase that
belongs to the membrane associated guanylate kinase family.
CASK regulates the trafﬁcking, targeting and signalling of
numerous presynaptic proteins including neurexins, APBA1
(Mint1) and ion channels,
46 and is also implicated in brain
development.
47 Interestingly, a C2B domain is also found in
Doc2-a (Double C2-like domains, a), a protein that belongs to
the same superfamily as RIMS3. DOC2A is one of w24 genes
located within the 16p11.2 microdeletion-duplication region that
has recently been detected in w1% of patients with autism.
81 11 2
Although the p.E177A variant was not found in a large
number of controls and was predicted to be deleterious using
SIFTand SNAP, further studies are needed to prove whether the
p.E177A substitution is pathogenic or not, as protein simulation
programs do not substitute for experimental conﬁrmation.
29 48
Only two of the three in silico methods we used predicted
a deleterious effect from the p.E177A variant. This is not
surprising, given that each program varies in methodology,
including differences in classiﬁcation approaches (eg, machine
learning vs rule based systems) and input information
(eg, sequence data, functional annotation, protein structure,
solvent accessibility).
29 31 We also identiﬁed one variant in
a control subject that was predicted to be deleterious. Only
Figure 3 Mutation analysis of RIMS3 identiﬁes two missense variants that segregate with autism and autism related phenotypes. (A) The pedigree for
family AU0247 shows that the p.E177A missense variant is present in a patient with autism (AU0247-03), in a sibling with Not Quite Autism (NQA)
(AU0247-04), and in the mother who presents with psychiatric symptoms. Chromatograms indicate the presence of the A/C substitution. The SIFT
program predicted the p.E177A substitution to be deleterious. (B) The pedigree for family AU0125 shows that the p.M260V missense variant is
present in two siblings with autism (AU0125-03 and AU0125-04) as well as in the father who presents with psychiatric symptoms, including
obsessiveecompulsive disorder (OCD). Chromatograms indicate the presence of the A/G substitution. The variant is not predicted to affect protein
function.
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Original articlelimited phenotype data are available for this subject, so we
cannot determine whether it is a benign or weakly pathogenic
variant. Detailed phenotypic assessment of this subject would
help distinguish between these possibilities.
In summary, our data demonstrate that heterozygous loss of
one or more of the 43 genes located within a w3.3 Mb interval
on chromosome 1p34.2p34.3 are associated with abnormal
development, including mental retardation, postnatal micro-
cephaly and autism. Furthermore, our data suggest but do not
prove conclusively that RIMS3 is an autism causative or
contributory gene. To our knowledge, this is the ﬁrst study to
suggest that mutations in a RIM protein may underlie autism or
other neurodevelopmental disorders. The identiﬁcation of puta-
tive mutations in RIMS3 is consistent with the identiﬁcation of
CNVs and intragenic mutations of other pre- and post-synaptic
proteins in patients with autism, andlends further support to the
hypothesis that abnormalities in synaptic development and
function underlie autism in some (and perhaps many) patients.
Functional studies of RIMS3 variants such as p.E177A should
provide additional insight into the role of pre-synaptic proteins in
autism. Finally, the rare association of microcephaly and autism
suggests that other gene(s) in the region are associated with brain
growth.
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Table 2 Phenotype analysis
AU012503 AU012504 AU024703 AU024704
Mutation M260V M260V E177A E177A
Sex Male Female Male Male
Ethnicity Non-Hispanic Non-Hispanic Non-Hispanic Non-Hispanic
Race White White White White
ADI-R
Age (years) at ADI-R 10 7 6 3
Social domain 11 19 24 9
Communication-verbal domain 17 13 20 16
Restricted, repetitive behavior domain 11 12 5 3
Classiﬁcation Autism Autism Autism NQA
Age of 1st words (months) 12 12 48 36
Age of 1st phrases (months) 16 14 54 38
Any language regression No No No No
Overall level of language Phrase speech Phrase speech Phrase speech Phrase speech
Any regression of other skills No H, P, SH, M No No
Anxiety None + None +
Aggression +++ +++ + +
Overactivity + + + +
History of seizures No Possible No No
Age ﬁrst steps (months) 14 11 11 13
Gait Abnormal Abnormal Hx abnormal Unusual
Coordination impairment (Gross/Fine) GF GF None GF
Savant skills Memory Drawing Drawing e
ADOS classiﬁcation Spectrum Autism Autism Autism
Physical measures and abnormalities
Age (years) at physical examination 12 10 7 5
Birth weight (g) 4309 3600 3374 2920
Height (cm) 154.9 139.7 50 e
Percentage 61 42 <3
Weight (kg) 80 31.8 ee
Percentage 97 29
Head circumference (cm) 57.7 51.8 e 49.4
Head circumference (%) 98 53 e 27
Ear length (cm) 6 5.7 5.5 5.1
Functioning/psychiatric
Age (years) at IQ testing 12 10 7 5
Verbal IQ 126 ee e
Non-verbal IQ 94 107 110 e
Depressive symptoms No Yes No No
OCD symptoms Yes Dx Yes No
Other diagnosis Anxiety, ADHD Bipolar, ADHD
Stimulants (current) Adderal
Other medications (current) Paxil, risperidone Depakote, clonidine Naltrexone none
ADHD Dx Dx Yes Yes
Sleep problems 0e1y o 0 e1y o 1 e2 yo Missing
Asst. reproduction None None None None
Handedness Right Right Right Right
ADHD, attention deﬁcit hyperactivity disorder; ADI-R, Autism Diagnostic Interview-Revised; ADOS, Autism Diagnostic Observation Schedule; H, loss of purposive hand use; M, motor; NQA, not
quite autism; OCD, obsessiveecompulsive disorder; P, play and imagination; SH, self help.
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